Taigen Biopharmaceuticals Holdings Ltd (TWO:4157) — Stock Price
Taigen Biopharmaceuticals Holdings Ltd (TWO:4157) is currently trading at NT$8.70 TWD, down 0.80% today. Over the past 52 weeks, shares have ranged between NT$7.90 and NT$15.60. This page tracks Taigen Biopharmaceuticals Holdings Ltd's live share price on the TWO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 4157 company net worth.
Taigen Biopharmaceuticals Holdings Ltd (4157) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Taigen Biopharmaceuticals Holdings Ltd's daily closing share price and trading volume on the TWO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Taigen Biopharmaceuticals Holdings Ltd Income Statement — Revenue, Profit & Earnings by Year
Taigen Biopharmaceuticals Holdings Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | NT$259.47 Million | NT$150.65 Million | NT$123.13 Million | NT$36.23 Million | NT$1.29 Billion |
| Cost of Revenue | NT$18.17 Million | NT$16.13 Million | NT$39.05 Million | NT$3.74 Million | NT$12.72 Million |
| Gross Profit | NT$241.30 Million | NT$134.52 Million | NT$84.08 Million | NT$32.49 Million | NT$1.28 Billion |
| Research & Development | NT$96.88 Million | NT$166.07 Million | NT$187.48 Million | NT$237.52 Million | NT$283.28 Million |
| SG&A | NT$75.02 Million | NT$90.55 Million | NT$98.90 Million | NT$72.64 Million | NT$99.06 Million |
| Total Operating Expenses | NT$190.08 Million | NT$272.75 Million | NT$258.78 Million | NT$310.16 Million | NT$382.34 Million |
| Operating Income | NT$69.39 Million | NT$-122.10 Million | NT$-174.70 Million | NT$-217.15 Million | NT$876.24 Million |
| EBITDA | — | — | NT$-147.09 Million | NT$-188.60 Million | NT$905.10 Million |
| EBIT | — | — | NT$-174.70 Million | NT$-217.15 Million | NT$876.24 Million |
| Interest Expense | NT$1.67 Million | NT$1.42 Million | NT$1.14 Million | NT$854.00K | NT$244.00K |
| Income Before Tax | NT$57.44 Million | NT$-32.88 Million | NT$143.49 Million | NT$-229.76 Million | NT$875.99 Million |
| Income Tax Expense | — | — | NT$6.76 Million | NT$7.40 Million | NT$100.37 Million |
| Net Income | NT$45.18 Million | NT$-38.58 Million | NT$136.73 Million | NT$-237.16 Million | NT$775.62 Million |
Taigen Biopharmaceuticals Holdings Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Taigen Biopharmaceuticals Holdings Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | NT$1.17 Billion | NT$1.17 Billion | NT$1.23 Billion | NT$1.05 Billion | NT$1.39 Billion |
| Total Current Assets | NT$1.12 Billion | NT$1.09 Billion | NT$1.11 Billion | NT$949.24 Million | NT$1.23 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | NT$881.66 Million | NT$945.68 Million | NT$663.34 Million | NT$656.39 Million | NT$559.46 Million |
| Net Receivables | NT$5.01 Million | NT$7.33 Million | NT$33.87 Million | NT$26.79 Million | NT$280.89 Million |
| Inventory | NT$76.10 Million | NT$42.71 Million | NT$34.15 Million | NT$15.35 Million | NT$17.88 Million |
| Property, Plant & Equipment | — | — | — | NT$56.60 Million | NT$80.43 Million |
| Goodwill | — | — | NT$12.88 Million | NT$10.79 Million | NT$20.16 Million |
| Total Liabilities | NT$92.38 Million | NT$91.96 Million | NT$110.94 Million | NT$76.98 Million | NT$139.11 Million |
| Total Current Liabilities | NT$83.11 Million | NT$46.08 Million | NT$47.89 Million | NT$51.32 Million | NT$89.88 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | NT$-299.97 Million | NT$-204.64 Million | NT$-311.47 Million |
| Total Stockholder Equity | NT$1.07 Billion | NT$1.08 Billion | NT$1.12 Billion | NT$970.03 Million | NT$1.25 Billion |
| Retained Earnings | NT$589.18 Million | NT$615.26 Million | NT$635.49 Million | NT$541.29 Million | NT$776.80 Million |
Taigen Biopharmaceuticals Holdings Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Taigen Biopharmaceuticals Holdings Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$20.93 Million | NT$-173.09 Million | NT$20.74 Million | NT$-21.27 Million | NT$629.07 Million |
| Capital Expenditures | NT$4.50 Million | NT$2.70 Million | NT$7.39 Million | NT$7.46 Million | NT$11.83 Million |
| Free Cash Flow | NT$16.42 Million | NT$-175.78 Million | NT$13.35 Million | NT$-28.73 Million | NT$617.24 Million |
| Investing Cash Flow | — | — | — | NT$-84.95 Million | NT$-306.07 Million |
| Financing Cash Flow | — | — | NT$-19.99 Million | NT$-15.84 Million | NT$-18.85 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | NT$-11.63 Million | NT$32.48 Million | NT$25.00 Million | NT$-4.99 Million | NT$40.03 Million |
| Depreciation | NT$17.47 Million | NT$24.83 Million | NT$27.61 Million | NT$28.55 Million | NT$28.86 Million |
| Change in Cash | NT$70.95 Million | NT$-300.52 Million | NT$130.65 Million | NT$-121.82 Million | NT$304.08 Million |
Taigen Biopharmaceuticals Holdings Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Taigen Biopharmaceuticals Holdings Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 02, 2026 | — | — | — |
| Nov 11, 2025 | — | — | — |
| May 13, 2025 | — | — | — |
| Mar 13, 2025 | — | — | — |
| Nov 11, 2024 | — | — | — |
| Mar 09, 2023 | -0.16 | — | — |
| Nov 02, 2022 | 0.02 | — | — |
| Mar 15, 2022 | -0.19 | — | — |